Legal & Regulatory

Traceability

Trade & Brand Protection

Brand & Product Security

Business and Finance

Containers & Shippers

Devices

Software

Cold Chain

Commercial Channels

Artificial Intelligence

Digitalization

Real World Data

Data & Technology

Manufacturing & Packaging

Supply Chain

Logistics & Transportation

Commercialization

Pricing

Trade & Channel

Market Access

Opinion

Adherence

HUB Services

Patient Assistance Programs

Patient Support

News

Pharma Pulse

Publications

Brand Insights

Webcasts

Resources

Conferences

Conference Coverage

Conference Listing

Events

Videos

Podcasts

Editorial Podcasts

Subscribe

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Commerce

Instagram

Facebook

LinkedIn

Threads

Soundcloud

Spotlight

Digital Editions

Security

Topics

Data and Technology

Legal and Regulatory

Supply Chain Logistics

1rem

 interview, Brandon Newman, Xevant’s CEO and founder, explores:

The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system

The role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved

How Xevant helps improve drug cost transparency efforts

Strategies for affordability Newman would offer the pharma industry that can be implemented immediately

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency. 

A Further Examination of Pharmacy Benefit Managers

The collaboration is powered by the discovery and development of obesity, type 2 diabetes, and cardiovascular disease treatments. 

Novo Nordisk, Valo Health Grow Partnership Centered Around Cardiometabolic Disease Therapies

The new form of the vaccine would remove the need for HCPs to combine the powder antigen and liquid adjuvant themselves prior to administering.

FDA Accepts Review of New GSK Prefilled Syringe Presentation

What is the value in US adults addressing these risks, and how do social determinants of health play a role?

The Association Between Social Risks and Nonadherence to Cancer Screening Guidelines

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today. 

Navigating Access and Reimbursement Through Uncertainty 

Is this level of involvement with HRSNs associated with higher burnout? 

The Connection Between Physician Engagement and Tackling Health-Related Social Needs 

Behind the Scenes of Being a Clinical Trial Participant

, Jon Kostas,executive director of the APP

 discusses how the main goals and priorities of the APP are to serve as a trusted industry voice in the realm of psychedelics, aiming to provide clarity in an area that is often confusing due to the wide range of information and varying compounds. The organization seeks to advance psychedelic treatments through the FDA approval process, making these therapies accessible, affordable, and covered by insurance. In addition to expanding access, the APP emphasizes patient safety, ensuring that individuals receive the correct dosage and undergo appropriate mental and physical screenings before treatment. The focus is also on establishing best practices and safety standards for psychedelic use, ensuring that only eligible and qualified patients pursue these treatments.

Kostas also explains why he believes there was a need for this type of resource, what went into the making the launch happen, and the current state of psychedelic research, while sharing a personal story surrounding his participation in a randomized clinical trial involving psilocybin.

A transcript of Kostas’ conversation with

Could you describe the double-blind, randomized clinical trial involving psilocybin that you participated in?

Start to finish, it was about 54 weeks, and then I believe we took like a five or so month break in between. How it worked was, I went in for a screening. I had about a month or two of preparation to get me ready on what I might experience during these psilocybin sessions, because they give you a high dose of psilocybin (if you get the psilocybin and you don't get the placebo). That's why we're really emphasizing the safety here, because there is hope. This saved my life, but I did this with medical doctors. I did this with PhDs. I did this in a hospital setting, so if anything bad were to happen, they'd know how to get me through it.

A lot of people should have hope that are struggling right now, or their family members are struggling, but I'd encourage them to do this through the proper channels, and right now, that's through FDA clinical trials. We’re on the cusp of FDA approval, so hopefully they can do this through the healthcare system in the near future, but you need preparation, and you need to be mentally prepared and physically healthy to go through these experiences.

That was a big part of the clinical trial I was in: the team, the psychological support, a lot of preparation, a lot of integration after, and the sessions themselves. I was there for about a whole day, I mean, eight hours, and you're really feeling the effects of the drugs for a good, maybe 4,5,6 hours, and then they keep you there to make sure you're okay. How I did this was that I was technically like an outpatient, where I showed up for the day in the morning, did my procedure, and then I had someone pick me up from the hospital after, so I think that's probably how it'll look and be implemented into our current system.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), describes the randomized clinical trial involving psilocybin that he participated in.

Addressing Misconceptions Surrounding Psychedelics 

Kostas also explains why he believes there was a need for this type of resource, and what went into the making the launch happen, while sharing a personal story surrounding his participation in a randomized clinical trial involving psilocybin.

What went into making the APP a reality, and what were some of the challenges that you faced throughout the process?

The biggest challenge was a lot of the misinformation about psychedelics and the stigma. As a former study participant, I was in a clinical trial about 10 years ago. In 2015, I entered it as a treatment-resistant patient for alcohol use disorder. I had tried everything to stop drinking. Nothing worked. I was terrified of psychedelics, but I was so desperate that this was the only shot I had at getting any help, and this worked as soon as my first of three psilocybin sessions.

Psilocybin is one of the compounds in hallucinogenic mushrooms. I had a synthesized version of that. I've never ingested mushrooms, and I haven't done psychedelics outside of this clinical trial. I stopped drinking after my very first session, and I haven't touched alcohol. I haven't craved alcohol, and I haven't craved psychedelics at all after leaving the trial. This worked almost like an antibiotic for me, and there is a lot of misinformation out there, such as, can you treat one drug with an addiction to another drug?

Alcohol is technically a drug. They're also studying this for opiate use disorder, methamphetamine use disorder, cocaine use disorder, nicotine. The early results look very promising, and I'm hopeful that we'll have a lot more options for patients in the coming years, but a lot of the lawmakers thought that I was still taking psychedelics every day, like a prescription pill, or that I might have gone to the jungle to do this, but I had been doing this clinical trial in New York at NYU.

The biggest challenge has been the misinformation. We've been relying heavily on our scientific advisors that are from the universities and academic researchers that have been doing this research for, in some cases, decades. Then, there are these biotechs that are actually getting this through drug development to hopefully make this a prescription and make this a viable treatment, and give another option to patients. They have their whole set of obstacles as well through the Schedule I drugs, so there have been a few different obstacles, but that's why we felt that this was a great time to get everyone together, get all the leaders together, to really drive that voice and steer the conversation of how we get the federal government to support this research and support giving new options to patients out there.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), addresses the importance of stopping the spread of misinformation when it comes to psychedelics.

Building a Voice for Psychedelic Research

Why did you believe there was a need for this type of resource?

We've been at this for a couple of years now with initial discussions. We’ve had great relationships prior to this—starting with the members—so we've always had an open line of communication. Our work prior to this was a lot of educational work for the decision makers. What we would do is facilitate getting the best subject matter experts in front of the decision makers in Congress or in the executive branch, to lead with the data and the scientific evidence out there. This naturally happened. The timing couldn't have been better, with a new Congress coming in and a new Administration coming in, so despite what party was in power or will be in power in the future, it's good to have an association to be that guiding voice into responsible research and hopefully, medical applications of these compounds.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), explains why this resource is an asset, specifically for research in the psychedelic space.

Goals of the Association for Prescription Psychedelics

What are the main goals and priorities of the APP?

There's a lot of different information out there about psychedelics. It could be very confusing. Even between specific compounds, it can get very confusing. What we plan to do is serve as the trusted industry voice to help advance these compounds through the FDA to actually make them accessible, affordable, and covered by insurance, [while promoting] patient safety, because you know exactly what you're getting—the precise dosage, proper mental and physical screenings—going into this treatment in order to see if you're eligible and qualified for it too, so best practices around that and safety standards.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), provides a peek into what the association has set out to accomplish.

Patient Support & Engagement

PC: Back in August, you penned an article on "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment." What was the premise of the piece, and why exactly do you believe the integration of AI-enabled solutions has the potential to boost patient support and engagement across numerous patient care settings?

The impetus for my partner, John Hamrick, and I to delve into this was what we saw from our pharmaceutical manufacturer clients. It’s really the need to really reach into the technology support and leverage that to make an impact on patient engagement. We sought to outline an understanding of where we are from an ecosystem perspective in those tools, and then to outline best practices in vetting these different types of solutions and then how we would go about implementing those. So, I’d say the outcomes have been very positive. Manufacturers are eager to look at ways to optimize the patient journey with technology support solutions. So, we’re very excited about next steps in that area.

PC: What industry challenges are at the forefront for Curatio, and how might those change heading into 2025?

I think back about the article, and you know, as I said, the impetus for moving forward with this, we look at the desire for manufacturers to really reach out and to provide solutions for patients. We see the Lilly team coming forward with LillyDirect for those three big areas that they have. We also see Pfizer moving forward with some similar offerings. From a trends perspective, we do see pharmaceutical manufacturers looking to leverage these tools to optimize the patient journey.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment," and upcoming industry challenges.  

Latest Conference Coverage

Trade & Channel Strategies 2024: Boosting Patient Support & Engagement Across Care Settings

PC: This morning, you were part of the ‘Patient-Centric 3.0 — How Direct-to-Patient is the New Commercialization Model’ panel. Can you provide a brief synopsis of the panel?

When we think about direct to patient, it's all about the concept of helping patients understand the disease state, drive awareness, and then help them get access to therapy. It's the whole ecosystem from helping them understand the situation that they may be in, talking to the patient community, and gaining access to physicians. Whether that’s real life, brick and mortar, and then ultimately helping them get on therapy because t's never been more complicated to get through this system than it is now.

PC: What key challenges do you see drug manufacturers facing when implementing direct-to-patient models, and how can these be addressed to improve accessibility?

When I come to this conference every year, I joke that it gets more complicated. You have challenges from payer contracts, reimbursement challenges for patients, difficulty for doctors to prescribe and support reimbursement, and so that's that all makes the whole process a lot more difficult for patients get out of therapy. It’s really about helping patients get easier and faster access to therapy and then through that process, helping them navigate the reimbursement piece, simplifying it, and driving for pricing and reimbursement transparency, then helping them get to the right place to fulfill the therapy.

The "Patient-Centered 3.0: How Direct to Patient is the New Commercialization Model" panel explored the evolving landscape of direct-to-patient (DTP) models in pharmaceutical commercialization. This approach emphasizes empowering patients to understand their disease states, raising awareness, facilitating access to therapy, and ensuring adherence. The panel discussed the complexity of navigating today’s healthcare ecosystem and how DTP models address these challenges.

Key obstacles identified include payer contracts, reimbursement hurdles, and prescribing difficulties faced by physicians. These factors collectively complicate patient access to therapies. DTP models aim to simplify the process by offering greater transparency around pricing and coverage, expediting access to medications, and supporting patients throughout their treatment journey. This support extends from initial prescription authorization to affordability assistance and refill reminders, ensuring patients remain adherent to prescribed therapies.

Patient service teams were highlighted as pivotal in improving adherence through education, ongoing support, and affordability programs. These teams help patients navigate insurance processes, manage prior authorizations, enroll in copay assistance, and access clinical resources. Effective tools include self-assessment platforms, telehealth services, and physician locators, which streamline access to care and reduce time to therapy.

DTP initiatives have also accelerated the speed of therapy delivery. By enabling real-time coordination between prescribers and payers, patients can receive medications in as little as one day. The panel noted that DTP approaches drive awareness during product launches, enhance patient engagement, and foster a more efficient healthcare ecosystem.

Looking ahead, the next evolution of patient-centric models will focus on simplifying the increasingly complex healthcare environment. Innovations could include payer reforms, improved pricing structures, and enhanced pathways to ensure faster, more affordable access to therapies while prioritizing patient outcomes. The ultimate goal remains a seamless, patient-focused experience that delivers optimal care at reduced complexity.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

Trade & Channel Strategies 2024: Key Challenges of Implementing Direct-to-Patient Models 

Shaping the Future of Commercialization

, Chase Feiger, MD, co-founder of Ostro emphasizes the value of AI technology in addressing challenges in digital commercialization within the life sciences industry. The main gap being addressed is the lack of personalized, intuitive, and engaging user experiences for healthcare professionals (HCPs) and patients, especially on digital platforms like brand websites. Feiger compares traditional digital experiences in life sciences to consumer-driven platforms like Netflix, where content is personalized based on past behavior and preferences. In the life sciences sector, however, regulatory constraints—such as the need for compliance with medical, legal, and promotional review processes—complicate this kind of personalization. Despite these challenges, AI and other consumer technology solutions can be adapted for this sector, prioritizing regulatory compliance while enhancing the user experience.

The solution, Ostro, was developed with this mindset: to create a digital experience for life sciences that balances personalization with strict regulatory standards. Feiger’s team includes experts from consumer tech, privacy law, and compliance fields to ensure that the platform is both effective and compliant. Ostro aims to transform the way HCPs and patients interact with medical content.

Feiger also shares the up-and-coming trends that he anticipates in relation AI and life sciences, and how the industry can position itself to capitalize on these trends.

A transcript of Feiger’s conversation with

What emerging trends do you foresee in the intersection of AI and life sciences, and how can we as an industry position ourselves to capitalize on these trends over the next 10-15 years?

First and foremost, I think that every single brand experience 10-15 years from now is going to be vastly different in that there will be no one-size-fits-all brand.com or brand experience—it's going to be one that's really driven by personalized engagement, i.e., one that's going to understand where I am from a health literacy perspective, where I am from an HCP specialty perspective. It's one that's going to be entirely focused on things like personalization. If we look more holistically in the industry, we've seen the introduction of new technologies being able to support things like digital twins and virtual clinical trials, i.e., being able to create virtual control group solutions—with companies like Flatiron Health. I still think that there is a tremendous amount of innovation to occur, specifically on that side of the sector as well, when it comes to clinical trial research and how clinical trials are run.

I also think we're still in the very early stages for things like AI for market access and value communication, i.e., being able to leverage market access strategies to and conjoining that with a lot of what's happening in artificial intelligence. You'll be able to forecast things like payer trends, being able to optimize formulary positioning for new therapies. I think there that we're in the very nascent stages of that as well. But really where I'm going to go, and everything I'm going to hit on is all going to come back down to largely the commercial side, this idea for patient and HCP as AI to drive true personalization.

If you think about it, that is the thing that we keep hearing across the board. We've been hearing about personalized medicine for a very long time. We continue to hear about personalized medicine, but we're not actually practicing personalized medicine right now. We're practicing evidence-based medicine, which is good because we have the evidence, we have the real-world data to support the clinical decisions that we're making as providers. Imagine an era where we're doing genomic sequencing, we're looking at things like proteomics. Imagine what we're going to be able to do on the personalized level, and having all of that data from a personalization perspective to be able to support very important clinical decisions that we make. I think we are in the very early stages of that, and it'll be very interesting to see what comes in the future. A lot of that is going to tie to commercialization methodologies in some very exciting ways.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

AI’s Role in Personalizing Life Sciences Digital Experiences

How valuable can AI technology be when it comes to tackling digital commercialization challenges—especially within the life sciences industry—and what gaps were you trying to bridge when creating Ostro?

If I were to ask you, what are the things that you take away when you compare a legacy experience to a consumerized experience, you would tell me primarily three things. You would say, Chase, I'm getting convenience, I'm getting personalization. You go, you log into your Netflix, you log into my Netflix, you're going to see very different sets of content based on other things that we've looked at in the past. You're going to see a very intuitive user experience, one that didn't require you to learn and to train on how to use it. It was just very naturally intuitive when you started using it. I like to say that when we think about things like artificial intelligence, when we think about things like what's happening within commercialization and life sciences, it's very similar, except the one constraint being, of course, that every piece of content in life sciences has to go through regulatory compliance review. It has to go through PRC [Promotional Review Committee], MLR [Medical, Legal and Regulatory].

But there are ways that a lot of these different technologies that we've seen utilized in the consumer space can be rebuilt and re-crafted with a regulatory compliance-first mindset, and that's what we did. We ranked regulatory compliance as number one when we looked at recreating a lot of these different novel software solutions and bringing them to this industry; [we’ve added] a former prosecutor to our team. The individual who ran data privacy over at McKinsey is on our team. We took this very, very seriously, and we partnered up with best-in-class consumer technology experts to rebuild these products. That's how we did it. When you ask, what is it that we actually did, and how valuable is it—if I'm an HCP and if I go to a brand.com, that HCP is a one-size-fits-all experience. If I receive a rep-triggered email as an HCP, a lot of that content is not really engaging and interactable. It doesn't enable me to ask the questions I want to ask. Maybe I'm looking for information on clinical trial information, looking for more efficacy, or MLA based information. I have to click around and try to go and find it. It doesn't personalize for me. 

If I'm a patient and I land on a brand.com, the content doesn't personalize based on my health literacy level, i.e., do I have the health literacy level of a sixth grader? Do I have the health literacy level of an HCP that's trying to learn more about this new cancer immunotherapeutic? It's different for all groups. This is where artificial intelligence is having the most impact in terms of being able to provide that personalization for both the patient, as well as the HCP, making it easier for them to find that information they're looking for in a way that they can digest it, in a way that they can comprehend it, in a way that they can actually understand it and take better action on their care—if you're a patient or if you're an HCP—to learn more about that therapeutic treatment option with less clicking, less thinking, less scrolling.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, discusses the value of AI technology when it comes to tackling digital commercialization challenges.

Enhancing Pharmacy Resilience 

, John Stefankiewicz, VP of Analytics, Cencora

explained that pharmacy deserts are increasingly prevalent due to the ongoing closure of pharmacies, which affects community access to essential healthcare services. In urban areas, the nearest pharmacy may be difficult to reach due to barriers like highways and inadequate public transport. In rural regions, residents may need to travel significant distances, sometimes 20 miles, only to find pharmacies closed after work hours. Pharmacies serve as critical points of care, especially during peak seasons for illnesses like flu, emphasizing the necessity of local access to pharmacists for timely prescription filling and healthcare support.

Pharmacy deserts are increasingly prevalent due to the ongoing closure of pharmacies, which affects community access to essential healthcare services. In urban areas, the nearest pharmacy may be difficult to reach due to barriers like highways and inadequate public transport. In rural regions, residents may need to travel significant distances, sometimes 20 miles, only to find pharmacies closed after work hours. Pharmacies serve as critical points of care, especially during peak seasons for illnesses like flu, emphasizing the necessity of local access to pharmacists for timely prescription filling and healthcare support. There is also a need for advocacy to enhance pharmacy reimbursement and ensure long-term viability. Stefankiewicz highlighted the ability to quickly develop and test solutions across different regions, adapting to legislative changes. The conversation also addresses the issue of pharmacy deserts, noting that closures affect both access and operational challenges for remaining pharmacies. A specific example illustrates how a rural pharmacy absorbed patients from a closed chain store, revealing the diverse challenges pharmacies face, including staffing and service mix. Overall, the focus is on collaborative solutions to support pharmacies in underserved areas.

A transcript of Stefankiewicz’s conversation with

What types of solutions are needed to support pharmacists and future-proof the resiliency of pharmacies?

Advocacy is really going to be one of the areas that opens up pharmacy reimbursement, which is critical for their viability long term. On top of that, our scope allows us to build and test solutions very fast. Our scale allows us to test these solutions across geographies. So as one state legislates certain rules, we can apply that, see what the results of that are, and even almost advocate on behalf of the pharmacy in other areas—either at the state, local, or federal level. That’s the beauty of how we're looking at pharmacy deserts, and how we're looking to solutions. On top of that, pharmacy deserts, and the solutions required at the pharmacy level, is very diverse. We think about pharmacy closures and the viability of pharmacy, but pharmacy deserts also impact that pharmacy that's still open.

We were talking to a pharmacist and a pharmacy owner, where the chain store in the rural area— already in a pharmacy desert—closed, and they were left filling all those scripts from that chain pharmacy. Things like staffing, pharmacy mix—those are the solutions that they're turning to us to partner with them to help solve. That blew my mind, because we've been thinking about it as low access, but a lot of the GNP [Good Neighbor Pharmacy] stores are onboarding these new patients from other areas, other stores, and other chains that are closing. It just goes back to the diverse set of solutions available to the pharmacies.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, describes the value of advocacy and other solutions in under-served areas.

KOL Collaboration Series: Enhancing Pharmacy Resilience 

What Are Pharmacy Deserts? 

 Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, noted that pharmacy deserts are communities without access to pharmacies, hindering residents' ability to fill prescriptions and access healthcare services. These areas are often also healthcare deserts. Definitions vary by location: urban areas lack pharmacies within a mile, suburban areas within two miles, and rural areas within ten miles. Approximately 35 million people live in pharmacy deserts, making this issue pressing. Factors contributing to their rise include reimbursement pressures, decreased foot traffic post-COVID, and the inability of pharmacies to bill for services beyond prescription filling. Independent pharmacies, often serving underserved communities with a majority of government-paid patients, are particularly affected. Zilka also alluded to legislation that is helping to improve patient access.

A transcript of Zilka’s conversation with 

What exactly are pharmacy deserts, and why have they become so prominent?

If you think about a pharmacy desert, it's kind of exactly how it sounds. It's communities where there is no pharmacy, where people cannot fill their prescriptions, but as you know, in many of these pharmacy deserts, they may also be healthcare deserts, where the pharmacy is already playing the role of providing necessary services to maintain good health all around, well beyond just dispensing prescriptions. The definition—which is kind of an industry standard of what a pharmacy desert is—is really where there's no pharmacy, meaning there's no care for the local residents and patients of that area. And it's a little different, depending on if you're urban, suburban or rural, but essentially, it's a one-mile radius. If you're in the city, if people live more than a mile away from the nearest pharmacy; if you're in the suburbs, it's two miles. If you go to more rural settings, then it's 10 miles. Our data shows us that there's an estimated 35 million people live in a pharmacy desert, meaning they don't have access to a pharmacist or perhaps healthcare in general. So that's what a pharmacy desert is.

You asked why we are talking about pharmacy deserts, and why they are more prevalent than perhaps they have been in the past. Candidly, it's just because pharmacies are of all sizes and shapes. Of course, we're here today representing independent pharmacies, but regardless of whether it's an independent or a chain pharmacy, they are really at risk of going out of business. You're probably reading about it in the news these days, but essentially, there're a few key factors that are driving that.

The first is reimbursement pressure. They are continually being reimbursed less for prescription drugs on a day-to-day basis. And then I think as importantly, when you think about COVID, it drove a lot of traffic into the pharmacies. Since COVID is behind us, the need isn't as great. They're not getting as much food foot traffic either, coming into the pharmacy as they were during COVID. It's a combination of reimbursement pressure along less foot traffic. but I think as importantly, not having a vehicle to bill for some of the services that they that they provide, goes well beyond filling prescriptions. What's interesting about independent specifically is that the makeup of their patient base is typically over 50% government paid, meaning state Medicaid or Part D. These are already underserved communities. These are where there's a strong need for a healthcare provider, and that's where they typically where they typically reside.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, clarifies the meaning behind pharmacy deserts, along with reasons for their increase in prominence. 

Patient Support

Latest News